UY36200A - SET OF SPECIFIC BIOMARKERS FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER - Google Patents

SET OF SPECIFIC BIOMARKERS FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER

Info

Publication number
UY36200A
UY36200A UY0001036200A UY36200A UY36200A UY 36200 A UY36200 A UY 36200A UY 0001036200 A UY0001036200 A UY 0001036200A UY 36200 A UY36200 A UY 36200A UY 36200 A UY36200 A UY 36200A
Authority
UY
Uruguay
Prior art keywords
liver cancer
diagnosis
specific biomarkers
prognosis
invasive diagnosis
Prior art date
Application number
UY0001036200A
Other languages
Spanish (es)
Inventor
Man Cornelia Wing Yin
Wai Norman Fung Man
Wai Benjamin Chi Yin
Wong Bing Lou
Original Assignee
Vision Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/321,870 external-priority patent/US9885718B2/en
Priority claimed from US14/321,867 external-priority patent/US9506925B2/en
Application filed by Vision Global Holdings Ltd filed Critical Vision Global Holdings Ltd
Publication of UY36200A publication Critical patent/UY36200A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

La presente invención se refiere a la identificación y elucidación de proteínas que puede actuar como marcadores novedoso para el diagnóstico y la prognosis de cánceres hepáticos. Específicamente, se refiere a un kit que permite la medición de diagnóstico y prognosis de autoanticuerpos en suero de pacientes con cáncer hepático. Provee un método de detección y cuantificación no invasivo, específico, sensible y económicamente eficaz mediante la evaluación de proteínas de cáncer hepático /antígenos tumorales validados,que incluye Bmi-1, VCC1, SUMO-4, RhoA, TXN, ET-1, UBE2C, HDGF2,FGF21, LECT2, SOD1, STMN4, Midkine, IL-17A o IL26.The present invention relates to the identification and elucidation of proteins that can act as novel markers for the diagnosis and prognosis of liver cancers. Specifically, it refers to a kit that allows the measurement of diagnosis and prognosis of serum autoantibodies of patients with liver cancer. Provides a non-invasive, specific, sensitive and economically effective method of detection and quantification through the evaluation of validated liver cancer proteins / tumor antigens, including Bmi-1, VCC1, SUMO-4, RhoA, TXN, ET-1, UBE2C , HDGF2, FGF21, LECT2, SOD1, STMN4, Midkine, IL-17A or IL26.

UY0001036200A 2014-07-02 2015-07-01 SET OF SPECIFIC BIOMARKERS FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER UY36200A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/321,870 US9885718B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
US14/321,867 US9506925B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer

Publications (1)

Publication Number Publication Date
UY36200A true UY36200A (en) 2016-01-29

Family

ID=55019816

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036200A UY36200A (en) 2014-07-02 2015-07-01 SET OF SPECIFIC BIOMARKERS FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER

Country Status (13)

Country Link
EP (1) EP3164711A4 (en)
JP (2) JP2017520763A (en)
KR (1) KR102086788B1 (en)
CN (2) CN107478842B (en)
AU (2) AU2014399919B2 (en)
CA (1) CA2939912C (en)
HK (2) HK1224370A1 (en)
MY (2) MY195045A (en)
NZ (1) NZ722492A (en)
SG (1) SG11201606106SA (en)
TW (1) TWI700493B (en)
UY (1) UY36200A (en)
WO (1) WO2016003479A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106383231B (en) * 2016-09-02 2020-03-17 四川大学 Marker combination for diagnosing liver cancer and application thereof
KR102175265B1 (en) 2019-03-13 2020-11-06 충남대학교산학협력단 Biomarker composition comprising TXNDC7 for diagnosis or predicting prognosis of hepatocellular carcinoma
CN110646615B (en) * 2019-08-27 2021-07-13 南方医科大学 Biological marker and treatment target of hepatic fibrosis and application thereof
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
CN113502328A (en) * 2021-05-27 2021-10-15 深圳市人民医院 Application of reagent for detecting expression level of marker in sample in preparation of kit for detecting or diagnosing breast cancer
CN113777295B (en) * 2021-09-15 2024-03-19 江南大学 High-sensitivity quantum dot probe for detecting tumor marker PD-L1, preparation method and application
CN113956344A (en) * 2021-10-14 2022-01-21 江南大学 Novel FGF analogue for treating liver cancer and application thereof
CN114113611B (en) * 2021-12-13 2023-07-14 郑州大学 Biomarker for liver cancer diagnosis and detection kit

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6449562B1 (en) * 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
US6893844B1 (en) * 1998-09-22 2005-05-17 Long Yu DNA encoding a new human hepatoma derived growth factor and producing method thereof
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
US20040241653A1 (en) * 2001-12-31 2004-12-02 Elena Feinstein Methods for identifying marker genes for cancer
GB0228900D0 (en) * 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP3960614B2 (en) * 2003-08-31 2007-08-15 株式会社イムノディア Anti-peptide antibody measurement method and vaccine candidate selection method for peptide vaccine
GB0406215D0 (en) * 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
CA2567987A1 (en) * 2004-06-18 2005-12-29 Gabriele Pestlin Use of protein pdx1 as a marker for breast cancer
JP5211315B2 (en) * 2006-07-25 2013-06-12 国立大学法人愛媛大学 Tumor marker, tumor diagnostic kit, and method for measuring tumor marker
EP2187216B1 (en) * 2007-08-10 2012-09-26 Hyogo College Of Medicine Novel liver cancer marker
US8512963B2 (en) * 2009-11-25 2013-08-20 The Johns Hopkins University Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples
US9523680B2 (en) * 2010-06-30 2016-12-20 Ambergen, Inc. Global Proteomic screening of random bead arrays using mass spectrometry imaging
JP5493130B2 (en) * 2010-08-25 2014-05-14 国立大学法人山口大学 Autoantibody detection method
JP2014507160A (en) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． Circulating biomarker
US20130130355A1 (en) * 2011-09-28 2013-05-23 Armune Biosciences, Inc. Method and system of particle-phage epitope complex

Also Published As

Publication number Publication date
TWI700493B (en) 2020-08-01
CA2939912A1 (en) 2016-01-07
JP2017520763A (en) 2017-07-27
AU2017232129A1 (en) 2017-10-12
AU2014399919B2 (en) 2019-10-24
MY195045A (en) 2023-01-04
CN107478842B (en) 2020-10-16
HK1224370A1 (en) 2017-08-18
WO2016003479A1 (en) 2016-01-07
AU2017232129B2 (en) 2018-10-25
TW201602579A (en) 2016-01-16
KR20170021234A (en) 2017-02-27
NZ722492A (en) 2019-09-27
SG11201606106SA (en) 2016-08-30
CA2939912C (en) 2019-04-16
HK1248803A1 (en) 2018-10-19
AU2014399919A1 (en) 2016-08-11
CN105319362A (en) 2016-02-10
EP3164711A1 (en) 2017-05-10
MY179845A (en) 2020-11-18
EP3164711A4 (en) 2018-05-23
CN105319362B (en) 2018-07-13
JP2020160082A (en) 2020-10-01
KR102086788B1 (en) 2020-03-09
CN107478842A (en) 2017-12-15

Similar Documents

Publication Publication Date Title
UY36200A (en) SET OF SPECIFIC BIOMARKERS FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER
CY1121723T1 (en) COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TUMOR TREATMENT
EA201791578A1 (en) PANEL OF BIOMARKERS FOR CANCER DETECTION
MX2017008421A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder.
BR112016027475A2 (en) kit, device and method for the detection of pancreatic cancer
BR112016029583A2 (en) ? esophageal cancer detection kit or device and detection method?
MX2021006791A (en) Methods and compositions for detecting misfolded proteins.
BR112016007864A2 (en) Method for cancer prognosis and metastasis treatment
BR112013004673A2 (en) biomarkers and treatment methods.
MA39776A (en) Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
BR112017003472A2 (en) antibodies, antibody fab fragment and method for treating an inflammatory disease
CY1122233T1 (en) METHOD FOR PREDICTING THE OUTCOME OF AFLIVERCEPT TREATMENT OF A PATIENT SUSPECTED TO HAVE CANCER
EA201790549A1 (en) PREDICTIVE AND PROGNOSTIC BIOMARKERS ASSOCIATED WITH ANTIANGIOGENIC TREATMENT OF MALIGNANT TUMOR
AR094403A1 (en) ANTI-HER3 ANTIBODY COMBINATION THERAPY
BR112016002845A2 (en) compositions and methods for treating complement-associated conditions
WO2015082416A8 (en) Novel rna-biomarkers for diagnosis of prostate cancer
BR112017006593A2 (en) method to detect ovarian cancer
MA40636A (en) Methods of detecting prostate cancer
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
MX2015017950A (en) Methods for treatment of ovarian cancer.
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
MX2016009490A (en) Novel assay to detect human periostin.
MX2016010499A (en) Systems and methods for identifying progesterone receptor subtypes.
WO2018187385A8 (en) Compositions and methods of diagnosing pancreatic cancer
CY1119430T1 (en) ANTI-S100A7 ANTIBODIES FOR TREATMENT AND CANCER DIAGNOSIS